Insider Transactions in Q2 2022 at Athira Pharma, Inc. (ATHA)
Insider Transaction List (Q2 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2022
|
Perceptive Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
1,101,362
+18.67%
|
$2,202,724
$2.99 P/Share
|
|
Jun 29
2022
|
Perceptive Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
270,000
+6.81%
|
$540,000
$2.99 P/Share
|
|
Jun 28
2022
|
Hans Moebius Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+15.88%
|
$20,000
$2.88 P/Share
|
|
Jun 23
2022
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
2,614
-4.33%
|
$5,228
$2.69 P/Share
|
|
Jun 23
2022
|
Rachel Lenington COO and CDO |
SELL
Open market or private sale
|
Direct |
4,193
-41.93%
|
$8,386
$2.69 P/Share
|
|
Jun 23
2022
|
Mark James Litton President and CEO |
SELL
Open market or private sale
|
Direct |
7,960
-5.83%
|
$15,920
$2.69 P/Share
|
|
Jun 23
2022
|
Glenna Mileson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,614
-2.34%
|
$5,228
$2.69 P/Share
|
|
Jun 23
2022
|
Mark Worthington General Counsel and CCO |
SELL
Open market or private sale
|
Direct |
2,614
-12.04%
|
$5,228
$2.69 P/Share
|
|
Jun 22
2022
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+14.22%
|
-
|
|
Jun 22
2022
|
Rachel Lenington COO and CDO |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+50.0%
|
-
|
|
Jun 22
2022
|
Mark James Litton President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+12.78%
|
-
|
|
Jun 22
2022
|
Glenna Mileson Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+8.21%
|
-
|
|
Jun 22
2022
|
Hans Moebius Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+18.88%
|
-
|
|
Jun 22
2022
|
Mark Worthington General Counsel and CCO |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+31.53%
|
-
|
|
Jun 08
2022
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+4.73%
|
$2,500
$1.35 P/Share
|
|
May 18
2022
|
Mark James Litton President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
757
+0.65%
|
$5,299
$7.06 P/Share
|
|
May 18
2022
|
Glenna Mileson Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,721
+1.66%
|
$12,047
$7.06 P/Share
|
|
May 18
2022
|
Hans Moebius Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,699
+4.9%
|
$11,893
$7.06 P/Share
|
|
May 18
2022
|
Mark Worthington General Counsel and CCO |
BUY
Grant, award, or other acquisition
|
Direct |
3,396
+22.48%
|
$23,772
$7.06 P/Share
|
|
May 18
2022
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
243
+0.51%
|
$1,701
$7.06 P/Share
|
|
Apr 11
2022
|
Glenna Mileson Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+2.91%
|
$30,000
$10.64 P/Share
|